HI
ADIL

Harbour Investments’s Adial Pharmaceuticals ADIL Stock Holding History

Harbour Investments’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5 Sell
3
-1
-25% -$4 ﹤0.01% 4651
2025
Q4 		$22 Buy
+4
New +$32 ﹤0.01% 3822

Other funds holding ADIL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MCM
Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Harbour Investments's ADIL Position: Q1 2026 in Review

Harbour Investments reduced its Adial Pharmaceuticals (ADIL) stake by 25% in Q1 2026, selling an estimated $4 and leaving 3 shares worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #4651.

Harbour Investments first reported a position in ADIL in Q4 2025 and has held it in 2 quarters since. The position peaked at $22 in Q4 2025. 14 funds tracked by Wall St. Rank hold ADIL as of Q1 2026.

  • Harbour Investments held 3 shares of Adial Pharmaceuticals worth $5 as of Q1 2026.
  • Harbour Investments sold 1 Adial Pharmaceuticals share in Q1 2026, an estimated $4.
  • Adial Pharmaceuticals made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #4651 holding.
  • Harbour Investments first reported a position in Adial Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Harbour Investments's Adial Pharmaceuticals position peaked at $22 in Q4 2025.
  • 14 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.